GlassScriptPhysician profile
Tiziana Anello
NPI 1295740686
$4,176.31
in general payments reported to CMS, 2019-2025
28 companies · $686 in 2025
The $686 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $341 · 2021: $724 · 2022: $748 · 2023: $563 · 2024: $687 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,070.52 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Kaleo, INC. | $315.81 | 2019-2024 | Auvi-Q |
| Tris Pharma INC | $281.38 | 2019-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $273.88 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $230.12 | 2022-2025 | Azstarys, Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $213.99 | 2020-2022 | |
| Pfizer INC. | $183.05 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $177.92 | 2021-2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $176.54 | 2024-2025 | |
| Neos Therapeutics, LP | $145.51 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Ars Pharmaceuticals Operations, INC. | $145.36 | 2025 | Neffy |
| Csl Behring | $124.99 | 2025 | Hizentra |
| Abbvie INC. | $124.41 | 2021-2022 | |
| Cranial Technologies, INC | $101.61 | 2021-2025 | Doc Band |
| Covis Pharma Gmbh | $83.63 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $71.77 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $67.48 | 2020-2023 | |
| Seqirus USA INC | $60.49 | 2022-2024 | Flucelvax |
| Vertical Pharmaceuticals, LLC | $55.17 | 2019-2020 | |
| Alk-Abello, INC | $54.55 | 2025 | Neffy, Grastek, Odactra |
| Adlon Therapeutics L.P. | $49.15 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $39.36 | 2019-2020 | |
| Oxford Immunotec USA INC | $28.84 | 2020 | |
| Shire North American Group INC | $27.36 | 2019 | |
| Aytu Biopharma, INC. | $24.44 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $18.67 | 2025 | Alvesco |
| Phadia US INC. | $15.63 | 2025 | Immunocap |
| Qiagen, LLC | $14.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiziana Anello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.